Here you can find the latest TOPADUR news & events.
TOPADUR announced that Pascal Brenneisen has been appointed CEO, effective April 1, 2023, on top of his Board member assignment.
Topical Wound Treatment with a NO-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice.
We are proud to be recognized as one of Switzerland's most promising scale-ups in 2022.
A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts.
Dual-Mode Vasodilator M119 Delivery to Hair Follicle via Dissolving Microneedle for Advanced Alopecia Treatment.
Diabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.
Do you need more information or references? Media contact